The research involvement and interests of Kabir Mody, M.D., focus on liver, pancreas and bile duct (hepatopancreaticobiliary) cancers. In particular, he studies novel therapeutics, therapeutic strategies, and circulating tumor DNA (ctDNA) as it relates to the diagnosis and treatment of these malignancies.
- Cancer. Dr. Mody studies liver cancers, including biliary tract cancers (cholangiocarcinomas), hepatocellular carcinoma (HCC) and ibrolamellar carcinoma, and pancreas cancer.
- ctDNA. Dr. Mody leads an internal Mayo Clinic research team, and also a national collaborative research team, exploring multiple aspects relating to the dynamics of ctDNA in the diagnosis, treatment and prognosis of patients with hepatopancreaticobiliary cancers.
- Novel therapeutics and novel therapeutic strategies. Dr. Mody is involved in multiple early-phase clinical trials exploring novel therapies. These include leading trials of multimodality and multidisciplinary strategies to treat hepatopancreaticobiliary malignancies.
- Lab-based models of liver cancer to predict therapeutic options for individualized patient care. Dr. Mody co-leads a team exploring the use of laboratory microcancer models to test and predict therapeutic efficacy of individualized immunotherapy strategies for patients with liver cancer.
Significance to patient care
Hepatopancreaticobiliary cancers are uncommon cancers, but are growing in incidence and are associated with poor prognosis and significant mortality. These cancers have had few treatment options, and this remains a dire need. Areas of great interest to Dr. Mody with potential to improve outcomes for patients are utilizing ctDNA to identify genomic alterations that could lend themselves to therapeutic options; identifying resistance mechanisms in the face of particular therapies; and enabling prognostication for patients after definitive therapies such as surgery and radiation.
Additionally, novel systemic therapies for liver, pancreas and biliary cancers are desperately needed. With the advent and growth of immunotherapeutic strategies, developing a way to individualize these therapies for patients remains a promising novel strategy for patients with these malignancies.
- Vice chair for clinical practice, Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, 2019-present
- Co-chair, Hepatobiliary Solid Tumor Disease Group, Mayo Clinic Cancer Center, 2018-present